Abstract
Angiogenesis is essential for tumor growth and progression and is mediated by possitive and negative regulators of vessel growth. Since angiogenic mediators found in patient serum have been postulated to reflect the angiogenic potential of a malignant tumor, we investigated the angiogenic activity in the serum of patients with transitional cell carcinoma (TCC). The data were correlated to tumor characteristics and the clinical course of the patients. Eightyone patients with transitional cell carcinoma and 53 control persons were included in the study. Preoperative serum samples were collected and both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were quantified by ELISA. Additionally, the serum evoked proliferative activity on human umbilical vein endothelial cells (HUVEC) was evaluated. Data were compared to the clinical course of the patients. Serum of tumor patients significantly enhanced the proliferative capacity of HUVEC, compared to cells grown in standard culture medium (p = 0.0032), but not when compared to serum from control persons. Serum from patients with superficial TCC and well differentiated tumors induced a significantly higher angiogenic response (ANGhi) than serum from patients with poorly differentiated and invasive carcinomas (ANG10; p=0.037). VEGF level of ANGhi serum was 384.22 ± 247.76 pg/ml (n=37) which significantly differed from mean VEGF level detected in ANG10 serum (247.72 ± 211.93 pg/ml, n=42; p=0.019). Similarly, mean bFGF levels were 9.58 ± 5.91 pg/ml in ANGhi serum versus 5.74 + 3.52 pg/ml) in ANG10 serum (p=0.0043). A negative correlation was established between VEGF/bFGF serum concentration and patient prognosis. The experiments demonstrate a positive correlation between VEGF and bFGF serum level and endothelial proliferation in vitro. The inverse relationship between angiogenic activity and tumor stage might disclose information about angiogenesis and tumor progression in TCC.
Keywords: transitional cell carcinoma, angiogenesis, stimulation, angiogenic activity
References
- 1. Folkman J, and Shing Y. Angiogenesis. J Biol Chem. 1999; 267: 10931–4. [PubMed] [Google Scholar]
- 2. Folkman J. Tumor angiogenesis In Wells SA, Jr, and Sharp PA, (Eds): Accomplishments in Cancer Research 1997. Philadelphia , Lippincott, Williams & Wilkins; 1998. pp. 32–44. [Google Scholar]
- 3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–64. [DOI] [PubMed] [Google Scholar]
- 4. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, Skinner DG, Cote RJ. Prognostic markers in bladder cancer: A contemporary review of the literature. J Urol. 1998; 160: 645–59. [DOI] [PubMed] [Google Scholar]
- 5. Messing EW, Catalona W. Urothelial tumors in the urinary tract, In Walsh PC, Retik AB, Vaughan ED, Jr., and Wein AJ, (Eds): Campbell's Urology. Seventh Edition. Philadelphia , W.B. Saunders Co; 1998. pp. 2327–410. [Google Scholar]
- 6. Dickinson AJ, Fox SB, Persad RA, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as a independent predictor of prognosis in invasive bladder carcinomas. Br J Urol. 1994; 74: 762–6. [DOI] [PubMed] [Google Scholar]
- 7. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol. 2001; 166: 1275–9. [PubMed] [Google Scholar]
- 8. Jeon SH, Lee SJ, Chang SG. Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors. Oncol Rep. 2001; 8: 1265–7. [DOI] [PubMed] [Google Scholar]
- 9. Inoue K, Chikazawa M, Fukata S, Yoshikawa C, Shuin T. Frequent administration of angiogenesis inhibitor TNP‐470 (AGM‐1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res. 2002; 8: 2389–98. [PubMed] [Google Scholar]
- 10. Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadju‐vant chemotherapy and radical cystectomy. Clin Cancer Res. 2000; 6: 4866–73. [PubMed] [Google Scholar]
- 11. Rogala E, Skopinska‐Rozewska E, Sommer E, Pastewka K, Chorostowska‐Wynimko J, Sokolnicka I, Kazon M. Assessment of the VEGF, bFGF, aFGF and IL8 angiogenic activity in urinary bladder carcinoma, using the mice cutaneous angiogenesis test. Anticancer Res. 2001; 21: 4259–63. [PubMed] [Google Scholar]
- 12. Blaheta RA, Kronenberger B, Woitaschek D, Weber S, Scholz M, Schuldes H, Encke A, Markus BH. Development of an ultrasensitive in vitro assay to monitor growth of primary cell cultures with reduced mitotic activity. J Immunol Methods 1998; 211: 159–69. [DOI] [PubMed] [Google Scholar]
- 13. Quentin T, Schlott T, Korabiowska M, Kathei N, Zoller G., Glaser F, Kunze E. Alteration of the vascular endothelial growth factor and angiopoietins‐1 and ‐2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res. 2004; 5: 2745–56. [PubMed] [Google Scholar]
- 14. Oliveira‐Ferrer L, Tilki D, Ziegeler G, Hauschild J, Loges S, Irmak S, Kilic E, Huland H, Friedrich M, Ergun S. Dual role of carcinoembryonic antigen‐related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res. 2004; 64: 8932–8. [DOI] [PubMed] [Google Scholar]
- 15. Prout GR, Griffin PP, Shipley WU. Bladder carcinoma as a systemic disease. Cancer 1979; 43: 2532–9. [DOI] [PubMed] [Google Scholar]
- 16. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315–28. [DOI] [PubMed] [Google Scholar]